PD-L1 status in breast cancer: Current view and perspectives
PD-L1 status in breast cancer: Current view and perspectives
复制标题
DOI：
10.1016/j.semcancer.2019.12.003
复制
发表时间：
2021-05-17
影响因子：
14.5
通讯作者：
Palazzo, Juan
中科院分区：
文献类型：
--
作者：
Vranic, Semir;Cyprian, Farhan S.;Palazzo, Juan
传统上，乳腺癌不被认为是一种特别具有免疫原性的肿瘤。然而，最近的发展表明，一些侵袭性三阴性乳腺癌是免疫原性的，表现出对化疗的抵抗力，预后不良。这些癌症已被证明表达被鉴定为免疫治疗靶点的分子。尽管取得了进展，但挑战仍然很多，包括确定可能从免疫疗法中受益的患者。分析这些样品和评估免疫原性的最佳方法也是主要挑战。因此，最准确和可靠地评估免疫细胞作为潜在靶点是当前乳腺免疫治疗研究中最重要的目标之一。在本综述中，我们简要讨论了乳腺癌中检查点抑制剂（PD-1/PD-L1）的调节机制，并探讨了PD-L1检测的预测方面。
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy and have a poor prognosis. These cancers have been shown to express molecules identified as targets for immunotherapy. Despite the advances, the challenges are many, and include identifying the patients that may benefit from immunotherapy. The best methods to analyze these samples and to evaluate immunogenicity are also major challenges. Therefore, the most accurate and reliable assessment of immune cells as potential targets is one of the most important aims in the current research in breast immunotherapy. In the present review, we briefly discuss the mechanisms of the regulation of checkpoint inhibitors (PD-1/PD-L1) in breast cancer and explore the predictive aspects in the PD-L1 testing.